Search

Your search keyword '"Kiraz, Sedat"' showing total 843 results
Start Over Author "Kiraz, Sedat"
843 results on '"Kiraz, Sedat"'

1. Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

Author

Duran, Emine, Ozturk, Zeynep Ozge, Bilgin, Emre, Büyükaşık, Yahya, Dizdar, Omer, Yardimci, Gozde Kubra, Farisogullari, Bayram, Özsoy, Zehra, Ayan, Gizem, Uzun, Gullu Sandal, Ekici, Mustafa, Unaldi, Erdinc, Kilic, Levent, Akdoğan, Ali, Karadag, Omer, Bilgen, Şule Apraş, Kiraz, Sedat, Kalyoncu, Umut, and Ertenli, Ali Ihsan

Published
2023
Full Text
View/download PDF

5. Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?

Author

İlgen, Ufuk, Karadağ, Ömer, Emmungil, Hakan, Küçükşahin, Orhan, Koca, Süleyman Serdar, Erden, Abdülsamet, Bes, Cemal, Alpay Kanıtez, Nilüfer, Dalkılıç, Ediz, Akar, Servet, Mercan, Rıdvan, Çınar, Muhammet, Kaşifoğlu, Timuçin, Gönüllü, Emel, Kimyon, Gezmiş, Ersözlü, Duygu, Atagündüz, Pamir, Kılıç, Levent, Ertenli, İhsan, Yazısız, Veli, Ateş, Aşkın, Kiraz, Sedat, and Kalyoncu, Umut

Published
2022
Full Text
View/download PDF

8. In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?

Author

Yagiz, Burcu, Coskun, Belkis Nihan, Pehlivan, Yavuz, Dalkilic, Ediz, Kiraz, Sedat, Yazisiz, Veli, Kucuksahin, Orhan, Erden, Abdulsamet, Kanitez, Nilufer Alpay, Kimyon, Gezmiş, Emmungil, Hakan, Bilge, Sule Yasar, Kasifoglu, Timucin, Bes, Cemal, Bolek, Ertugrul Cagri, Bilgin, Emre, Karatas, Ahmet, Kelesoglu, Bahar, Ersozlu, Duygu, Gonullu, Emel Orge, Mercan, Ridvan, Yilmaz, Sedat, Karadag, Omer, Akar, Servet, Ertenli, Ihsan, and Kalyoncu, Umut

Published
2021
Full Text
View/download PDF

10. The validity, reliability, and responsiveness of a new biopscyhosocial questionnaire for patients with systemic lupus erythematosus.

Author

Demirtekin, Merve, Yardımcı, Gözde Kübra, Avcı, Hanife, Öksüz, Sevim, Bilgen, Şule Apraş, Kiraz, Sedat, and Unal, Edibe

Subjects
SYSTEMIC lupus erythematosus, MEDICAL personnel, BODY image, INTRACLASS correlation, SOCIAL anxiety, EXERCISE therapy, CRONBACH'S alpha
Abstract

In recent years, the importance of holistic care in individuals with systemic lupus erythematosus (SLE) has been emphasized, and therefore a measurement tool that evaluates biopsychosocial impact is needed. This study was conducted to determine the validity, reliability, and responsiveness of the Cognitive Exercise Therapy Approach-Biopsychosocial Questionnaire (BETY-BQ) in individuals with SLE. Lupus Quality of Life (LupusQoL), Short Form-36 (SF-36), Health Assessment Questionnaire (HAQ), and Hospital Anxiety and Depression Scale (HADS) were used for the validity. For reliability, evaluations were repeated at 1 -week intervals and for responsiveness, the same scales were re-administered at 3-month intervals to 30 patients. BETY-BQ showed moderate to high correlations with LupusQoL subparameters (rho = −0.522 to −0.718, p < 0.001), moderate to very high correlations with SF-36 subparameters (r = −0.826 to rho = 0.594, p < 0.001), high correlations with HAQ and HADS-D (rho = 0.735, p < 0.001; rho = 0.622, p < 0.001, respectively) and a moderate correlation with HADS-A (rho = 0.571, p < 0.001). In the test-retest method the correlation between the responses was very high (r = 0.989, p < 0.001). The intraclass correlation coefficient (r = 0.944, p < 0.001) and Cronbach's alpha value were found to be excellent (0.952). BETY-BQ showed moderate correlations with LupusQoL subparameters (the body image r = −0.443, p = 0.014; planning rho = −0.529, p = 0.003; fatigue r = −0.484, p = 0.007; intimate relationships rho = −0.421, p = 0.02), SF-36 social function subparameter (rho = −0.427, p = 0.019) and anxiety and depression subparameter of HADS (rho = 0.418, p = 0.021; r = 0.507, p = 0.004, respectively). BETY-BQ which was found as a valid, reliable, and responsive scale in individuals with SLE, was presented to healthcare professionals for use in clinical and research studies as a scale that can be preferred in the evaluation of biopsychosocial status of individuals with SLE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates

Author

Sandal Uzun, Güllü, primary, Taghiyeva, Arzu, additional, Çakır, İbrahim Y., additional, Moral, Kenan, additional, Yardımcı, Gözde Kübra, additional, Bölek, Ertuğrul Ç., additional, Farisoğulları, Bayram, additional, Duran, Emine, additional, Ayan, Gizem, additional, Özsoy, Zehra, additional, Ekici, Mustafa, additional, Unaldı, Erdinç, additional, Germe, Şerife A., additional, Fırlatan, Büşra, additional, Kart‐Bayram, Gözde S., additional, Bilgin, Emre, additional, Kılıç, Levent, additional, Karadağ, Ömer, additional, Akdoğan, Ali, additional, Bilgen, Şule A., additional, Kiraz, Sedat, additional, Ertenli, Ali Ihsan, additional, and Kalyoncu, Umut, additional

Published
2023
Full Text
View/download PDF

13. Physiciansʼ Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database

Author

Tekgoz, Emre, Colak, Seda, Yardimci, Kubra G., Kucuksahin, Orhan, Cinar, Muhammet, Yilmaz, Sedat, Kasifoglu, Timucin, Bes, Cemal, Yagiz, Burcu, Erden, Abdulsamet, Kilic, Levent, Kanitez, Nilufer A., Ertenli, Ali I., Coskun, Belkis N., Ediboglu, Elif D., Mercan, Ridvan, Kiraz, Sedat, Yazisiz, Veli, Karadag, Omer, Atagunduz, Pamir, and Kalyoncu, Umut

Published
2022
Full Text
View/download PDF

18. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy—findings from the TReasure database: a 5-year follow-up study

Author

Yagiz, Burcu, primary, Lermi, Nihal, additional, Coskun, Belkis N, additional, Dalkilic, Ediz, additional, Kiraz, Sedat, additional, Erden, Abdulsamet, additional, Ertenli, Ihsan, additional, Duran, Emine, additional, Bilgin, Emre, additional, Yılmaz, Recep, additional, Ateş, Aşkın, additional, Tufan, Abdurrahman, additional, Küçük, Hamit, additional, Mercan, Ridvan, additional, Cinaklı, Haluk, additional, Akar, Servet, additional, Yaşar Bilge, Nazife Ş, additional, Kaşifoglu, Timucin, additional, Türk, Sümeyye M, additional, Gonullu, Emel Orge, additional, Bes, Cemal, additional, Alpay Kanitez, Nilufer, additional, Emmungil, Hakan, additional, Kalyoncu, Umut, additional, and Pehlivan, Yavuz, additional

Published
2023
Full Text
View/download PDF

20. Bizarre Cutaneous Ulcers due to Self-Administered Intravenous Dexketoprofen Trometamol.

Author

Akdogan, Neslihan, Elcin, Gonca, and Kiraz, Sedat

Abstract

Systemic non-steroidal anti-inflammatory drug use may result in various cutaneous complications including maculopapular rash, fixed drug eruption, urticaria, and angioedema most frequently. However extensive cutaneous ulcers in relation to intravenous dexketoprofen trometamol use has not been identified before although cutaneous ulcers have been described in association with several opioids. Herein, we would like to present a 27-year-old male with a 1-year history of progressive deep cutaneous ulcers due to long term abusive intravenous use of dexketoprofen trometamol. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. A new biopsychosocial questionnaire (BETY-BQ) for patients with ankylosing spondylitis

Author

KİRAZ, SEDAT, ÜNAL, EDİBE, Oksüz, Sevim, Soy, Mehmet, ÖNEN, FATOŞ, and VEREP, UĞUR

Abstract

Introduction: Scales for biopsychosocial evaluation of patients are limited. This study assessed the validity, reliability, and responsiveness of a Cognitive Exercise Therapy Approach-Biopsychosocial Questionnaire (Bilişsel Egzersiz Terapi Yaklaşımı-Biopsychosocial Questionnaire; BETY-BQ) in patients with ankylosing spondylitis (AS). Methods: Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S), Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL), Hospital Anxiety and Depression Scale (HADS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI), were selected to investigate the validity of the BETY-BQ. Spearman's correlation coefficient was used as the data were not normally distributed. For scale reliability, the test-retest method was performed, Intraclass Correlation Coefficient (ICC) was calculated and Cronbach's alpha (α) coefficient was checked for internal consistency. The same scales were applied to patients under medical treatment at 3-month intervals for the determination of responsiveness. Results: A total of 157 individuals took part, including 106 (67.5%) male participants and 51 (32.5%) female participants, with a mean age of 43.86±11.60 years. The correlations of BETY-BQ with the HAQ-S, ASQoL, HADS, BASDAI, and BASFI were very high to moderate (r = 0.819 to r = 0.583, p

Published
2023

22. The predictors of paradoxical reactions especially psoriasis with biologic therapy from the TReasure database: a 5-year follow-up study

Author

Erden, ABDULSAMET, Dalkilic, Ediz, Coskun, Belkis N, Lermi, Nihal, Yagiz, Burcu, Pehlivan, Yavuz, Kalyoncu, Umut, Emmungil, Hakan, Bes, Cemal, Gonullu, Emel Orge, Türk, Sümeyye M, Kaşifoglu, Timucin, Yaşar Bilge, Nazife Ş, Akar, Servet, Bilgin, Emre, Duran, Emine, Ertenli, Ihsan, Kiraz, Sedat, Cinaklı, Haluk, Mercan, Ridvan, Küçük, Hamit, Tufan, Abdurrahman, Ateş, Aşkın, and Yılmaz, Recep

Published
2023

23. The first effect of COVID-19 pandemic on starting biological disease modifying anti-rheumatic drugs: outcomes from the TReasure real-life database

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kiraz, Sedat; Dalkilic, Ediz; Kimyon, Gezmis; Mercan, Ridvan; Karadag, Omer; Bes, Cemal; Kilic, Levent; Akar, Servet; Ates, Askin; Emmungil, Hakan; Ertenli, Ihsan; Pehlivan, Yavuz; Coskun, Belkis Nihan; Yagiz, Burcu; Ersozlu, Duygu; Gonullu, Emel; Cinar, Muhammet; Kasifoglu, Timucin; Koca, Suleyman Serdar; Karasu, Ugur; Kucuksahin, Orhan; Kalyoncu, Umut, School of Medicine, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kiraz, Sedat; Dalkilic, Ediz; Kimyon, Gezmis; Mercan, Ridvan; Karadag, Omer; Bes, Cemal; Kilic, Levent; Akar, Servet; Ates, Askin; Emmungil, Hakan; Ertenli, Ihsan; Pehlivan, Yavuz; Coskun, Belkis Nihan; Yagiz, Burcu; Ersozlu, Duygu; Gonullu, Emel; Cinar, Muhammet; Kasifoglu, Timucin; Koca, Suleyman Serdar; Karasu, Ugur; Kucuksahin, Orhan; Kalyoncu, Umut, and School of Medicine

Abstract

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic., NA

Published
2023

24. Do we underestimate musculoskeletal ultrasonography in the diagnosis of polymyalgia rheumatica with or without giant cell arteritis?

Author

Uzun, Güllü Sandal, Yardımcı, Gözde Kübra, Moral, Kenan, Kılıç, Levent, Bilgen, Şule Apraş, Kiraz, Sedat, Ertenli, İhsan, and Karadağ, Ömer

Subjects
ULTRASONIC imaging, POLYMYALGIA rheumatica, GIANT cell arteritis, RHEUMATISM, MEDICAL personnel
Abstract

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

25. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry

Author

Karadag, Omer, primary, Farisogullari, Bayram, additional, Yagiz, Burcu, additional, Erden, Abdulsamet, additional, Ademoglu, Zeliha, additional, Kimyon, Gezmis, additional, Bilge, Nazife Sule, additional, Icacan, Ozan Cemal, additional, Kilic, Levent, additional, Coskun, Belkis Nihan, additional, Ersozlu, Emine Duygu, additional, Kucuksahin, Orhan, additional, Mercan, Ridvan, additional, Koca, Suleyman Serdar, additional, Gonullu, Emel, additional, Cinar, Muhammet, additional, Akar, Servet, additional, Emmungil, Hakan, additional, Kasifoglu, Timucin, additional, Bes, Cemal, additional, Omma, Ahmet, additional, Pehlivan, Yavuz, additional, Kiraz, Sedat, additional, Ertenli, Ihsan, additional, Dalkilic, Ediz, additional, and Kalyoncu, Umut, additional

Published
2023
Full Text
View/download PDF

26. The impact of antiphospholipid antibodies in Takayasu arteritis

Author

ŞENTÜRK, ESRA FIRAT, primary, ERDEN, ABDULSAMET, additional, SARI, ALPER, additional, ARMAĞAN, BERKAN, additional, KILIÇ, LEVENT, additional, KALYONCU, UMUT, additional, KARADAĞ, ÖMER, additional, BİLGEN, ŞAZİYE ŞULE APRAŞ, additional, KİRAZ, SEDAT, additional, ERTENLİ, ALİ İHSAN, additional, and AKDOĞAN, ALİ, additional

Published
2023
Full Text
View/download PDF

27. Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database

Author

Duygu Ersözlü, Emine, primary, Ekici, Mustafa, additional, Nihan Coşkun, Belkis, additional, Özlem Badak, Suade, additional, Bilgin, Emre, additional, Kalyoncu, Umut, additional, Yağız, Burcu, additional, Pehlivan, Yavuz, additional, Küçükşahin, Orhan, additional, Erden, Abdulsamet, additional, Solmaz, Dilek, additional, Atagündüz, Pamir, additional, Kimyon, Gezmiş, additional, Beş, Cemal, additional, Çolak, Seda, additional, Mercan, Rıdvan, additional, Kaşifoğlu, Timuçin, additional, Emmungil, Hakan, additional, Alpay Kanıtez, Nilüfer, additional, Ateş, Aşkın, additional, Serdar Koca, Süleyman, additional, Kiraz, Sedat, additional, and Ertenli, İhsan, additional

Published
2022
Full Text
View/download PDF

30. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis

Author

Armağan, Berkan, primary, Kılıç, Levent, additional, Farisoğulları, Bayram, additional, Yardımcı, Gözde Kübra, additional, Bilgin, Emre, additional, Bölek, Ertuğrul Çağrı, additional, Karadağ, Ömer, additional, Bilgen, Şule Apraş, additional, Kiraz, Sedat, additional, Ertenli, İhsan, additional, and Kalyoncu, Umut, additional

Published
2022
Full Text
View/download PDF

37. The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database

Author

Kanıtez, Nilüfer Alpay, Kiraz, Sedat, Dalkılıç, Ediz, Kimyon, Gezmiş, Mercan, Rıdvan, Karadağ, Ömer, and Beş, Cemal

Subjects
rheumatoid arthritis, coronavirus disease 2019, Spondyloarthritis, Society Classification Criteria, Reliability, Biological disease-modifying anti-rheumatic drug, Bath Ankylosing-Spondylitis
Abstract

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.

Published
2022

38. The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database

Author

Kanitez, Nilufer Alpay, Kiraz, Sedat, Dalkılıç, Ediz, Kimyon, Gezmiş, Mercan, Rıdvan, Karadağ, Ömer, and Beş, Cemal

Subjects
rheumatoid arthritis, coronavirus disease 2019, Spondyloarthritis, Society Classification Criteria, Reliability, Biological disease-modifying anti-rheumatic drug, Bath Ankylosing-Spondylitis
Abstract

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.

Published
2022

39. Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry

Author

Farisoğulları, Bayram, primary, Yardımcı, Gözde Kübra, additional, Sarı, Alper, additional, Bilgin, Emre, additional, Bölek, Ertuğrul Çağrı, additional, Duran, Emine, additional, Kılıç, Levent, additional, Akdoğan, Ali, additional, Karadağ, Ömer, additional, Apraş Bilgen, Şule, additional, Ertenli, Ali İhsan, additional, Kiraz, Sedat, additional, and Kalyoncu, Umut, additional

Published
2022
Full Text
View/download PDF

42. The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results

Author

Farisoğulları, Bayram, primary, Yardımcı, Gözde Kübra, additional, Sarı, Alper, additional, Armağan, Berkan, additional, Bilgin, Emre, additional, Bölek, Ertuğrul Çağrı, additional, Duran, Emine, additional, Ayan, Gizem, additional, Özsoy, Zehra, additional, Sandal Uzun, Güllü, additional, Kılıç, Levent, additional, Akdoğan, Ali, additional, Karadağ, Ömer, additional, Apraş Bilgen, Şule, additional, Ertenli, Ali İhsan, additional, Kiraz, Sedat, additional, and Kalyoncu, Umut, additional

Published
2021
Full Text
View/download PDF

44. Clinical and laboratory factors associated with the bamboo spine in patients with axial spondyloarthritis: are there clues for the bamboo spine?

Author

Atagündüz, Pamir, primary, Kiraz, Sedat, additional, Akar, Servet, additional, Küçükşahin, Orhan, additional, Erden, Abdulsamet, additional, Aksoy, Aysun, additional, Coşkun, Belkis Nihan, additional, Yağiz, Burcu, additional, Bes, Cemal, additional, Alpay Kanitez, Nilüfer, additional, Kilic, Levent, additional, Karadağ, Ömer, additional, Kaşifoğlu, Timuçin, additional, Emmungil, Hakan, additional, Cinar, Muhammet, additional, Kimyon, Gezmiş, additional, Yazisiz, Veli, additional, Ateş, Aşkın, additional, Ersözlü, Duygu, additional, Gönüllü, Emel, additional, Mercan, Rıdvan, additional, Ertenli, İhsan, additional, and Kalyoncu, Umut, additional

Published
2021
Full Text
View/download PDF

46. The impact of antiphospholipid antibodies in Takayasu arteritis.

Author

FIRAT ŞENTÜRK, Esra, ERDEN, Abdulsamet, SARI, Alper, ARMAĞAN, Berkan, KILIÇ, Levent, KALYONCU, Umut, KARADAĞ, Ömer, APRAŞ BİLGEN, Şule, KİRAZ, Sedat, ERTENLİ, İhsan, and AKDOĞAN, Ali

Subjects
TAKAYASU arteritis, PHOSPHOLIPID antibodies, MISCARRIAGE, SYMPTOMS, VENOUS thrombosis, UNIVERSITY faculty
Abstract

Background/aim: The significance of antiphospholipid antibodies (aPL) is controversial in Takayasu arteritis (TA). This study was conducted to explore the frequency of aPL and their association with disease-related complications in TA. Materials and methods: This cross-sectional study was conducted to investigate the presence of anti-cardiolipin (aCL), anti-beta 2 glycoprotein- 1(aβ2G1) antibodies, and lupus anticoagulant (LA) in TA patients. TA patients admitted to the Department of Rheumatology of Hacettepe University Faculty of Medicine between December 2015 and September 2016 who fulfilled the American College of Rheumatology (ACR) classification criteria for TA were consecutively enrolled in the study. Patients were grouped according to aPL positivity and compared in terms of disease manifestations, type of vascular involvement at diagnosis, and vascular complications/interventions attributable to TA. Results: Fifty-three TA (49 female) patients were enrolled in the study. We detected 9 (16.9%) patients with IgM and/or IgG aβ2G1 and/or LA positivity. There were no patients with positive aCL. All aβ2G1 titers were low. There were no differences in terms of symptoms, signs, type of vascular involvement, the number of patients with disease-related complications or vascular interventions/surgery between aPL (+) and aPL(-) groups (p > 0.05 for all). The number of patients with thrombotic lesions was similar between the groups (p > 0.05). There were no patients with a history of venous thrombosis or on anticoagulant treatment in the aPL(+) group. Only 1 patient with IgM aβ2G1 (+) had a history of pregnancy loss. Conclusion: Our results indicate that aPL positivity is not rare in TA. On the other hand, all aPL titers were low and no differences were found in the frequency of disease-related complications between aPL(+) and aPL(-) patient groups. Only TA patients with atypical manifestations with high suspicion of aPL-related complications should be considered to be investigated for aPL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data

Author

Kalyoncu, Umut, primary, Bilgin, Emre, additional, Erden, Abdulsamet, additional, Satış, Hasan, additional, Tufan, Abdurrahman, additional, Tekgöz, Emre, additional, Ateş, Aşkın, additional, Coşkun, Belkıs Nihan, additional, Yağız, Burcu, additional, Küçükşahin, Orhan, additional, Yazısız, Veli, additional, Kimyon, Gezmiş, additional, Bes, Cemal, additional, Başıbüyük, Canberk Sami, additional, Alkan, Serdar, additional, Cesur, Teoman Yusuf, additional, Ertenli, İhsan, additional, and Kiraz, Sedat, additional

Published
2021
Full Text
View/download PDF

50. Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study

Author

Renauer, Paul A., Saruhan-Direskeneli, Guher, Coit, Patrick, Adler, Adam, Aksu, Kenan, Keser, Gokhan, Alibaz-Oner, Fatma, Aydin, Sibel Z., Kamali, Sevil, Inanc, Murat, Carette, Simon, Cuthbertson, David, Hoffman, Gary S., Akar, Servet, Onen, Fatos, Akkoc, Nurullah, Khalidi, Nader A., Koening, Curry, Karadag, Omer, Kiraz, Sedat, Langford, Carol A., Maksimowicz-McKinnon, Kathleen, McAlear, Carol A., Ozbalkan, Zeynep, Ates, Askin, Karaaslan, Yasar, Duzgun, Nursen, Monach, Paul A., Ozer, Huseyin T. E., Erken, Eren, Ozturk, Mehmet A., Yazici, Ayten, Cefle, Ayse, Onat, Ahmet Mesut, Kisacik, Bunyamin, Pagnoux, Christian, Kasifoglu, Timucin, Seyahi, Emire, Fresko, Izzet, Seo, Philip, Sreih, Antoine G., Warrington, Kenneth J., Ytterberg, Steven R., Cobankara, Veli, Cunninghame-Graham, Deborah S., Vyse, Timothy J., Pamuk, Omer N., Tunc, Ercan S., Dalkilic, Ediz, Bicakcigil, Muge, Yentur, Sibel P., Wren, Jonathan D., Merkel, Peter A., Direskeneli, Haner, and Sawalha, Amr H.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results